A survey of the off-label use of mood stabilizers in a large psychiatric hospital

Journal of Psychopharmacology

Volumn 19, Issue 4, 2005, Pages 402-407

  Haw, Camilla ^a   Stubbs, Jean ^a  

^a ST ANDREW S HOSPITAL   (United Kingdom)

Author keywords

Aggression; Anticonvulsants; Mania; Mood disorders; Mood stabilizers; Off label prescribing; Schizophrenia; Survey; Unlicensed indications

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; AGED; AGGRESSION; DRUG LABELING; DRUG MONITORING; FEMALE; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MOOD DISORDER; OFF LABEL PRESCRIPTION; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOSIS; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; TREATMENT INDICATION;

ADOLESCENT; ADULT; AFFECT; AGED; DATA COLLECTION; DRUG UTILIZATION; FEMALE; GREAT BRITAIN; HOSPITALS, PSYCHIATRIC; HUMANS; INFORMED CONSENT; LITHIUM; MALE; MENTAL DISORDERS; MIDDLE AGED; PRESCRIPTIONS, DRUG; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; PSYCHOTROPIC DRUGS;

EID: 22344455208     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881105053307     Document Type: Review

References (28)

1. Anonymous (1992) Prescribing unlicensed drugs or using drugs for unlicensed indications. Drug Ther Bull 30: 97-99
2. Berlant J, van Kammen D (2002) Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 63: 15-20
3. British Medical Association and Royal Pharmaceutical Society of Great Britain (2003) British National Formulary No. 46. British Medical Association and Royal Pharmaceutical Society of Great Britain, London
4. Calabrese J R, Vieta E, Shelton M D (2003) Latest maintenance data on lamotrigine in bipolar disorder. European Neuropsychopharmacology 13 Suppl 2: S57-S66
5. Courtney M E, Acomb J A, Lovatt V (1995) A pharmacy-controlled lithium clinic. Psychiatr Bull 19: 15-17
6. Department of Constitutional Affairs (2004) Mental Capacity Bill. The Stationery Office, London
7. Dorevitch A, Aronzon R, Zilberman L (1993) Medication maintenance of chronic schizophrenic outpatients by a psychiatric pharmacist: 10-year follow-up study. J Clin Pharm Ther 102: 183-186
8. Douglas-Hall P, Fuller A, Gill-Banham S (2001) An analysis of off-licence prescribing in psychiatric medicine. Pharm J 267: 890-891
9. Dursun S, Deakin J (2001) Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J Psychopharmacol 15: 297-301
10. Dursun S, McIntosh D, Milliken H (1999) Clozapine plus lamotrigine in treatment-resistant schizophrenia. Arch Gen Psychiatry 56: 950
11. Evins A (2003) Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry 64: S9-S14
12. Guy W (ed.) (1976) Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology (Revised). National Institute of Mental Health; US Department of Health, Education and Welfare Publication (ADM) 91-338, Rockville, Maryland, USA
13. Healy D, Nutt D (1998) Prescriptions, licences and evidence. Psychiatr Bull 22: 680-684
14. Henry V (1999) Off-label prescribing. Legal implications. J Legal Med 20: 365-383
15. Iancu I, Yitzhak R, Kotler M (2002) Antiepileptic drugs in posttraumatic stress disorder. Clin Neuropharmacol 25: 225-229
16. Lindenmayer J, Kotsaftis A (2000) Use of sodium valproate in violent and aggressive behaviours: a critical review. J Clin Psychiatry 61: 123-128
17. Lowe-Ponsford F, Baldwin D (2000) Off-label prescribing by psychiatrists. Psychiatr Bull 24: 415-417
18. Macritchie K, Geddes J, Scott J, Haslam D, Goodwin G (2004) Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (Cochrane Review). The Cochrane Library, Issue 2. John Wiley & Sons, Ltd, Chichester, UK
19. Medicines Compendium (2004) Datapharm Communications Ltd, Epsom, UK
20. Saba G, Dumortier S, Kalalou K, Benadhira R, Degrassat K, Glikman J, Januel D (2002) Lamotrigine clozapine combination in refractory schizophrenia: three cases. J Neuropsychiatry Clin Neurosci 14: 86
21. Simhandl C, Meszaros K (1992) The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychosis: a review. J Psychiatry Neurosci 17: 1-14
22. Suppes T (2002) Review of the use of topiramate for treatment of bipolar disorders. J Clin Psychopharmacol 22: 599-609
23. Tariot P, Erb R, Podgorski C, Cox C, Patel S, Jakimovitch L, Irvine C (1998) Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 155: 54-61
24. Taylor D, Starkey K, Ginary S (2000) Prescribing and monitoring of carbamazepine and valproate - a case note review. Psychiatr Bull 24: 174-177
25. Taylor D, McConnell H, Duncan-McConnell D, Kerwin R (2003) The Maudsley Prescribing Guidelines, 7th edn. Martin Dunitz, London
26. Tiihonen J, Hallikainen T, Ryynänen O, Repo-Tiihonen E, Kotilainen I, Eronen M, Toivonen P, Wahlbeck K, Putkonen A (2003) Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry 54: 1241-1248
27. World Health Organization (1992) The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. World Health Organization, Geneva
28. Young J, Hillbrand M (1994) Carbamazepine lowers aggression: a review. Bull Am Acad Psychiatry Law 22: 53-61